Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

August 14, 2025

Study Completion Date

August 14, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

TTI-101

Orally via a tablet.

DRUG

Placebo

Orally via a tablet.

Trial Locations (28)

10017

New York University Langone Pulmonary and Critical Care Associates, Brooklyn

10029

Icahn School of Medicine at Mount Sinai, New York

17033

Penn State Health Milton S. Hershey Medical Center, Hershey

18020

Saint Luke's University Hospital - Bethlehem, Bethlehem

19140

Temple University Hospital, Philadelphia

22042

Inova Fairfax Medical Campus, Falls Church

27403

Pulmonix, Greensboro

29425

The Medical University of South Carolina, Charleston

30322

Emory University Hospital, Atlanta

32610

University of Florida, Gainesville

33125

UHealth - University of Miami Health Systems, Miami

33765

Saint Francis Sleep Allergy and Lung Institute, Clearwater

35233

The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham

37067

Clinical Trials Center of Middle Tennessee, Franklin

52242

University of Iowa Hospitals and Clinics, Iowa City

60153

Loyola University Medical Center, Maywood

60611

Northwestern University, Chicago

60637

University of Chicago Medicine, Chicago

63017

The Lung Research Center, Chesterfield

75069

Metroplex Pulmonary and Sleep Center, McKinney

75246

Baylor Scott & White Center for Advanced Heart & Lung Disease, Dallas

77030

Baylor College of Medicine, Houston

University of Texas Health Science Center at Houston (UT Health), Houston

80045

University of Colorado School of Medicine, Aurora

92037

University of California San Diego, La Jolla

92868

University of California Irvine (UCI) Health, Orange

70112-2600

Tulane University School of Medicine, New Orleans

27103-4007

Salem Chest Specialists, Winston-Salem

All Listed Sponsors
lead

Tvardi Therapeutics, Incorporated

INDUSTRY

NCT05671835 - Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter